BridgeBio (BBIO) Director Andrea Ellis Exercises Options, Sells Shares

What Happened
Andrea Ellis, a director of BridgeBio Pharma (BBIO), exercised 17,167 stock options (strike $16.75) on 2026-07-09 and sold the same 17,167 shares in an open-market transaction the same day. The option exercise required $287,547 at the $16.75 strike; the subsequent sale generated $1,442,028 in gross proceeds (sale price $84.00). The filing shows the derivative conversion associated with the exercise as a related disposition.

Key Details

• Transaction date: 2026-07-09; Form 4 filed 2026-07-13 (timely).
• Exercise: 17,167 shares at $16.75 = $287,547 (reported as an acquired derivative exercise).
• Sale: 17,167 shares at $84.00 = $1,442,028 (open-market sale).
• Related derivative disposition reported at $0.00 as part of the conversion.
• Footnote F1: Sale was effected under a Rule 10b5-1 trading plan adopted December 3, 2025.
• Footnote F2: The underlying option fully vested on June 21, 2026 (vesting schedule noted).
• Shares owned after transaction: Not disclosed in this filing.

Context
This was an exercise of options followed by an immediate open-market sale (commonly a cashless exercise and sale). The sale was executed under a pre-established 10b5-1 plan, which indicates the trade was prearranged rather than a spontaneous market-timing decision. The filing is factual and does not indicate insider intent.